Literature DB >> 17207096

The gamma-aminobutyric acid-B receptor agonist baclofen attenuates responding for ethanol in ethanol-dependent rats.

Brendan M Walker1, George F Koob.   

Abstract

BACKGROUND: Gamma-aminobutyric acid-B (GABA(B)) receptor agonists have been shown to suppress operant self-administration of ethanol in nondependent rats. However, little work has focused on the effects of GABA(B) receptor agonists on self-administration of ethanol in dependent animals.
METHODS: In the present experiment, the GABA(B) receptor agonist baclofen was tested for the ability to modulate both fixed- (FR) and progressive-ratio (PR) responding for ethanol in rats while nondependent and subsequently after ethanol dependence induction. Following the acquisition and stabilization of baseline operant ethanol self-administration and after dependence induction, baclofen [0.0, 0.5, 1, 2, and 4 mg/kg, intraperitoneal (IP)] was tested on FR-1 responding for ethanol. The ability of baclofen (2.0 mg/kg) to affect responding under a PR schedule of reinforcement was also evaluated. Dependence was induced in the animals by subjecting them to a 1-month intermittent vapor-exposure period in which animals were exposed to ethanol vapor for 14 h/d. Following the 1-month period, the vapor-exposed animals resumed FR-1 and PR baclofen drug testing (doses as described above) in the operant chambers at a time point corresponding to the animals being 6 hours into withdrawal (i.e., 6 hours after the ethanol vapor had been discontinued for that day).
RESULTS: Baclofen (0.0, 0.5, 1, 2, and 4 mg/kg, IP) dose-dependently decreased ethanol self-administration in both nondependent and dependent rats on a FR schedule of reinforcement. However, the dose of baclofen that significantly reduced responding for ethanol was shifted to the left in the ethanol vapor-exposed animals, indicating an increased sensitivity to baclofen in animals that were chronically exposed to ethanol. When tested using a PR schedule of reinforcement, there was a significant increase in the breakpoint for the vapor-exposed animals (i.e., the animals were willing to work more in a dependent state). Baclofen (2.0 mg/kg, IP) suppressed intake for both nondependent and dependent animals.
CONCLUSIONS: Ethanol dependence produced increased self-administration of ethanol as reflected in increased ethanol intake and increased responding on a PR schedule of reinforcement. As baclofen suppressed ethanol self-administration and showed evidence of increased potency in dependent animals, the present experiment suggests that the GABA(B) receptor could be a potential pharmacotherapeutic target for the treatment of chronic alcoholism.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17207096      PMCID: PMC2768469          DOI: 10.1111/j.1530-0277.2006.00259.x

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  34 in total

1.  Regulation of somatodendritic dopamine release in the ventral tegmental area by opioids and GABA: an in vivo microdialysis study.

Authors:  M A Klitenick; P DeWitte; P W Kalivas
Journal:  J Neurosci       Date:  1992-07       Impact factor: 6.167

2.  Effects of baclofen and nitrendipine on ethanol withdrawal responses in the rat.

Authors:  S E File; A Zharkovsky; K Gulati
Journal:  Neuropharmacology       Date:  1991-02       Impact factor: 5.250

3.  Intra-amygdala muscimol decreases operant ethanol self-administration in dependent rats.

Authors:  A J Roberts; M Cole; G F Koob
Journal:  Alcohol Clin Exp Res       Date:  1996-10       Impact factor: 3.455

4.  Operant self-administration of sweetened versus unsweetened ethanol: effects on blood alcohol levels.

Authors:  A J Roberts; C J Heyser; G F Koob
Journal:  Alcohol Clin Exp Res       Date:  1999-07       Impact factor: 3.455

5.  Modulation of A10 dopamine neurons by gamma-aminobutyric acid agonists.

Authors:  P W Kalivas; P Duffy; H Eberhardt
Journal:  J Pharmacol Exp Ther       Date:  1990-05       Impact factor: 4.030

6.  Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis.

Authors:  E Merlo Pich; M Lorang; M Yeganeh; F Rodriguez de Fonseca; J Raber; G F Koob; F Weiss
Journal:  J Neurosci       Date:  1995-08       Impact factor: 6.167

7.  Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal.

Authors:  S Rassnick; S C Heinrichs; K T Britton; G F Koob
Journal:  Brain Res       Date:  1993-03-05       Impact factor: 3.252

8.  GABA antagonist and benzodiazepine partial inverse agonist reduce motivated responding for ethanol.

Authors:  S Rassnick; E D'Amico; E Riley; G F Koob
Journal:  Alcohol Clin Exp Res       Date:  1993-02       Impact factor: 3.455

Review 9.  A physiological role for GABAB receptors and the effects of baclofen in the mammalian central nervous system.

Authors:  U Misgeld; M Bijak; W Jarolimek
Journal:  Prog Neurobiol       Date:  1995-07       Impact factor: 11.685

10.  GABAA receptor antagonism in the extended amygdala decreases ethanol self-administration in rats.

Authors:  P Hyytiä; G F Koob
Journal:  Eur J Pharmacol       Date:  1995-09-05       Impact factor: 4.432

View more
  110 in total

1.  Effects of prolonged ethanol vapor exposure on forced swim behavior, and neuropeptide Y and corticotropin-releasing factor levels in rat brains.

Authors:  Brendan M Walker; David A Drimmer; Jennifer L Walker; Tianmin Liu; Aleksander A Mathé; Cindy L Ehlers
Journal:  Alcohol       Date:  2010-08-12       Impact factor: 2.405

2.  GABA(A) receptors in the dorsal raphé nucleus of mice: escalation of aggression after alcohol consumption.

Authors:  Aki Takahashi; Carolyn Kwa; Joseph F Debold; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2010-06-30       Impact factor: 4.530

3.  Corticosteroid-dependent plasticity mediates compulsive alcohol drinking in rats.

Authors:  Leandro F Vendruscolo; Estelle Barbier; Joel E Schlosburg; Kaushik K Misra; Timothy W Whitfield; Marian L Logrip; Catherine Rivier; Vez Repunte-Canonigo; Eric P Zorrilla; Pietro P Sanna; Markus Heilig; George F Koob
Journal:  J Neurosci       Date:  2012-05-30       Impact factor: 6.167

Review 4.  Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.

Authors:  Megan M Yardley; Lara A Ray
Journal:  Addict Biol       Date:  2016-02-01       Impact factor: 4.280

5.  The peroxisome proliferator-activated receptor alpha agonist fenofibrate attenuates alcohol self-administration in rats.

Authors:  Colin N Haile; Therese A Kosten
Journal:  Neuropharmacology       Date:  2017-01-11       Impact factor: 5.250

Review 6.  Potential of GABAB Receptor Positive Allosteric Modulators in the Treatment of Alcohol Use Disorder.

Authors:  Paola Maccioni; Giancarlo Colombo
Journal:  CNS Drugs       Date:  2019-02       Impact factor: 5.749

7.  The role of matrix metalloproteinase-9 in negative reinforcement learning and plasticity in alcohol dependence.

Authors:  Bok Soon Go; Sunil Sirohi; Brendan M Walker
Journal:  Addict Biol       Date:  2019-01-16       Impact factor: 4.280

8.  Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence.

Authors:  Brendan M Walker; George F Koob
Journal:  Neuropsychopharmacology       Date:  2007-05-02       Impact factor: 7.853

9.  Maladaptive behavioral regulation in alcohol dependence: Role of kappa-opioid receptors in the bed nucleus of the stria terminalis.

Authors:  Chloe M Erikson; Gengze Wei; Brendan M Walker
Journal:  Neuropharmacology       Date:  2018-07-31       Impact factor: 5.250

10.  Corticotropin-releasing factor-1 receptor antagonists decrease heroin self-administration in long- but not short-access rats.

Authors:  Thomas N Greenwell; Cindy K Funk; Pietro Cottone; Heather N Richardson; Scott A Chen; Kenner C Rice; Eric P Zorrilla; George F Koob
Journal:  Addict Biol       Date:  2009-04       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.